Testosterone Update

CHAIRPERSON
Graham Jackson, MB(Hons)
Consultant Cardiologist
London Bridge Hospital
London, England
BMI Shirley Oaks Hospital
Croydon, England
Honorary Consultant
Guy's Hospital
St Thomas' Hospital
London, England

FACULTY
Wayne J.G. Hellstrom, MD
Professor of Urology
Chief, Section of Andrology
Tulane University Medical Center
New Orleans, Louisiana

INTENDED AUDIENCE
Primary
Endocrinologists, urologists, primary care physicians, cardiologists, specialists, and other healthcare providers interested in the management and treatment of hypogonadism and related men's health concerns.
Secondary
Endocrine/urology nurses, NPs/PAs, diabetologists, HIV/AIDS treaters, psychologists/sex therapists, managed care clinicians, and clinical pharmacists interested in the management and treatment of hypogonadism and related men's health concerns.

STATEMENT OF NEED
Fueled by easy access to medications over the Internet, abuse of anabolic-androgenic steroids (AAS) is a major public health concern. Discussions between patients and clinicians are sometimes clouded and do not distinguish between inappropriate use of AAS or performance-enhancing drugs and appropriate testosterone therapy for patients with hypogonadism. The goal of this newsletter is to promote clarity in discussions about illegitimate and legitimate sources of medications and information available on the Internet.

EDUCATIONAL OBJECTIVES
Patient outcomes could be measurably improved if physicians were better able to...

Clearly communicate about the dangers of purchasing medications over the Internet, a practice often unrecognized by clinicians and underreported by patients
Recognize symptoms of anabolic-androgenic steroid (AAS) abuse, such as testicular atrophy, gynecomastia, and infertility
Distinguish between AAS abuse and the appropriate administration of testosterone therapy in cases of documented hypogonadism

ACCREDITATION AND CERTIFICATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Dannemiller and CogniMed Inc. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by e-mail following activity participation and upon completion and electronic submission of the posttest and evaluation to Dannemiller. A link to the evaluation form is provided upon completion of the activity. If you have any questions about your certificate, please e-mail cme@dannemiller.com.

CONTENT REVIEW STATEMENT
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

DISCLOSURE STATEMENT
It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity have disclosed that there will not be discussion about the use of products for non–FDA-approved indications.

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:

Dannemiller Staff
Michelle Montgomery, Director of Continuing Education, has nothing to disclose.
Mark Nadeau, MD, Content Reviewer, has nothing to disclose.

CogniMed Inc. Staff
Roseann MacLachlan, Senior Program Manager, has nothing to disclose.
Estelle Perera, Director, Scientific Affairs, and Medical Writer, has nothing to disclose.
Elizabeth Stanton, Editor, has nothing to disclose.

Faculty
Wayne J.G. Hellstrom, MD, receives research support from Auxilium Pharmaceuticals, Inc.; Coloplast; Endo Pharmaceuticals; Johnson & Johnson; Medtronic, Inc.; Slate Pharmaceuticals, Inc.; and VIVUS, Inc. He is a consultant for American Medical Systems; Auxilium Pharmaceuticals, Inc.; Coloplast; Cook Group Incorporated; Endo Pharmaceuticals; Johnson & Johnson; Lilly USA, LLC; Medtronic, Inc.; and VIVUS, Inc. He serves on the speakers bureaus of Auxilium Pharmaceuticals, Inc.; Cook Group Incorporated; Endo Pharmaceuticals; Johnson & Johnson; Lilly USA, LLC; Medtronic, Inc.; Slate Pharmaceuticals, Inc.; and VIVUS, Inc.

Graham Jackson, MB(Hons), serves on the speakers bureaus of Bayer AG, Eli Lilly and Company, and Pfizer Inc.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.